Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan Medoxomil for Coronary Atherosclerosis and EAT Volume
NCT02360956Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olmesartan in Coronary atherosclerosis (CAD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Coronary atherosclerosis progression detected by CCTA at 12 months and Epicardial Adipose Tissue (EAT) volume detected by CCTA at 12 months. Status: unknown.
02
Drugs
olmesartan
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT02360956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360956.